Sun Pharmaceuticals Industries Q2FY18 consolidated net profit declines 59.2% yoy : Mixed Estimates
Sun Pharmaceuticals Industries Ltd Q2FY18
Consolidated Results Q2FY18: (Rs. in crore)Q2FY18YoY (%)
EBITDA Margin (%)
Net Profit (adjusted)
912.12[59.2]***EBITDA margin change is bps
Last updated on
Sun Pharmaceutical Industries reported consolidated results for the quarter came in mixed versus street estimates. Revenue for the quarter came in 3.1 % lower than the estimated figure of Rs. 6861 crore. EBITDA for the quarter came in 1.3 % higher than the estimated figure of Rs. 1357 crore. And lastly, net profit for the quarter came in 13.7 % higher than the estimated figure of Rs. 802 crore.
Sun Pharmaceutical Industries consolidated revenue for the quarter came in at Rs. 6650.34 crore, registering 19.5% yoy decline.
EBITDA for the quarter fell by 56.6% yoy to Rs. 1375.61 crore with a corresponding margin contraction of 1767 bps. EBITDA margin for the quarter stood at 20.7%. This margin contraction was aided by 10.4% increase in its employee benefit expenses.
The PAT for the quarter came in at Rs. 912.12 crore, yoy decline of 59.2%. This was due to 193% increase in its finance cost.
Sun Pharmaceuticals Industries Ltd ended at Rs. 526.15, down by 6.35 points or 1.19% from its previous closing of Rs. 532.50 on the BSE.
The scrip opened at Rs. 532 and touched a high and low of Rs. 537.50 and Rs. 517.50 respectively. A total of 64,17,679(NSE+BSE) shares were traded on the counter. The stock traded below its 200 DMA.
Let’s block ads! (Why?)
Via:: Stock – India Infoline